Loading clinical trials...
Loading clinical trials...
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Conditions
Interventions
NovoTTF-200T
Pembrolizumab
+1 more
Locations
90
United States
Central Alabama Research
Birmingham, Alabama, United States
Western Regional Medical Center, LLC
Goodyear, Arizona, United States
St. Jude Herritage Medical Group
Fullerton, California, United States
Hoag Family Cancer Institute - Hoag Memorial Hospital
Newport Beach, California, United States
Sutter Institute for Medical Research
Sacramento, California, United States
Florida Cancer Affiliates - Ocala Oncology
Ocala, Florida, United States
Start Date
July 31, 2024
Primary Completion Date
October 1, 2028
Completion Date
October 1, 2028
Last Updated
December 17, 2025
NCT06996782
NCT06975293
NCT06343402
NCT06955988
NCT06512051
NCT07175220
Lead Sponsor
NovoCure GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions